Scynexis (NASDAQ: SCYX) announced the initiation of a Phase 1 clinical study of SCY-770, an AMP-activated protein kinase (AMPK) activator ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE